MedTrace Logo

A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes

NCT00400283 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-02-24

No results posted yet for this study

Summary

This trial is conducted in Europe. A seven day dose escalation study in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

NNC 55-0414

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-19
Primary Completion
2001-05-03
Completion
2001-05-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400283 on ClinicalTrials.gov